Katrina Kao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katrina Kao has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Scott Rodig
Harvard Medical School, Boston, Massachusetts
51 shared publications - Kathleen L. Pfaff
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA
50 shared publications - Catherine J. Wu
Dana-Farber Cancer Institute
31 shared publications - Christina Coppola
Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
31 shared publications - David R. Patton
Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD
31 shared publications - David Sims
National Cancer Institute, Frederick, MD, United States
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S4: Tumor immune microenvironment in a colorectal cancer patient with acquired resistance to pembrolizumab and trebananib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S4: Tumor immune microenvironment in a colorectal cancer patient with acquired resistance to pembrolizumab and trebananib.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors